NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Tuesday,Benzinga reports. The firm currently has a $34.00 price target on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, October 16th. BTIG Research reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, NRx Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Stock Down 3.0%

NASDAQ:NRXP opened at $3.21 on Tuesday. The company has a fifty day moving average of $2.93 and a 200 day moving average of $2.76. NRx Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $6.01. The firm has a market capitalization of $63.59 million, a P/E ratio of -1.43 and a beta of 1.74.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently raised its position in NRx Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 27.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,255 shares of the company’s stock after buying an additional 37,598 shares during the quarter. Geode Capital Management LLC owned approximately 1.00% of NRx Pharmaceuticals worth $562,000 as of its most recent SEC filing. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.